<DOC>
	<DOCNO>NCT02156466</DOCNO>
	<brief_summary>This multicenter , Phase 1 , randomize , double-blind , placebo-controlled trial subject moderate severe psoriasis ass safety , tolerability , immunogenicity , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) efficacy multiple subcutaneous ascend dos MSB0010841 ( Anti-interleukin-17A/F [ Anti-IL-17A/F ] Nanobody ) .</brief_summary>
	<brief_title>Multiple Ascending Dose Trial MSB0010841 ( Anti-IL17A/F Nanobody ) Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Chronic plaque psoriasis least 6 month screen Greater equal ( &gt; = ) 10 % BSA plaques Psoriasis Area Severity Index ( PASI ) &gt; =12 Static Physician 's Global Assessment ( sPGA ) &gt; =3 ( score range 0 [ clear disease ] 5 [ severe disease ] ) screen baseline visit Other protocol define inclusion criterion could apply Any condition , include protocolspecified laboratory finding finding medical history pretrial assessment Investigator 's opinion constitutes risk contraindication subject 's participation trial could interfere trial objective , conduct evaluation Currently form nonplaque psoriasis specify protocol Drug induce psoriasis Biological treatment specify protocol , within 3 month prior Day 1 Systemic immunosuppressant phototherapy specify protocol , within 1 month prior Day 1 Use anticoagulant medication and/or antiplatelet medication define protocol Use aspirin define protocol Topical corticosteroid treatment lowstrength lowermid strength corticosteroid face , scalp , axilla , and/or groin within 1 month prior Day 1 Any previous treatment agent target interleukin ( IL ) 17 , IL12 and/or IL23 specify protocol Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>MSB0010841</keyword>
	<keyword>Anti-IL17A/F Nanobody</keyword>
	<keyword>M1095</keyword>
</DOC>